Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas

Luca Lavra, Alessandra Ulivieri, Cinzia Rinaldo, Roberto Dominici, Marco Volante, Emidio Luciani, Armando Bartolazzi, Francesco Frasca, Silvia Soddu, Salvatore Sciacchitano

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Galectin-3 (Gal-3) is an anti-apoptotic molecule of the j-galactoside-binding lectin family. Gal-3 is down-regulated by wt-p53 and this repression is required for p53-induced apoptosis. Since poorly differentiated thyroid carcinomas (PDTCs) and anaplastic thyroid carcinomas (ATCs) frequently harbour p53 mutations, we asked whether Gal-3 expression and activity could be influenced by such mutations in these tumours. We found a positive correlation between Gal-3 expression and p53 mutation in human thyroids and in thyroid carcinoma cell lines (TCCLs) harbouring different p53 mutations. Gal-3 was over-expressed in most ATCs and TCCLs, especially those with the most frequently detected p53 mutation (p 53R273H). Over-expression of p53 R273H in twop53-null cells (SAOS-2 and SW-1736) as well as in two wt- p53-carrying TCCLs (TPC-1 and K1), stimulated Gal-3 expression, while interference with p53R273H endogenous expression in ARO cells down-regulated Gal-3 expression. Conversely, over-expression of wt-p53 in ARO cells restored the inhibitory effect on Gal-3 expression. ARO cells are highly resistant to apoptosis and express both p53 and Gal-3, which are increased upon cisplatin treatment. Interference with Gal-3 expression in these cells stimulated their chemosensitivity. In conclusion, gain-of-function p53 mutant acquires the de novo ability to stimulate Gal-3 expression and to increase chemoresistance in ATCs.

Original languageEnglish
Pages (from-to)66-75
Number of pages10
JournalJournal of Pathology
Volume218
Issue number1
DOIs
Publication statusPublished - May 2009

Fingerprint

Galectin 3
Mutation
Thyroid Neoplasms
Cell Line
Anaplastic Thyroid Carcinoma
Apoptosis
Galactosides
Null Lymphocytes
Lectins
Cisplatin
Thyroid Gland

Keywords

  • Anaplastic thyroid carcinoma (ATC)
  • Apoptosis
  • Chemoresistance
  • Clonogenic assay
  • Galectin-3
  • Human thyroid carcinoma cell lines
  • P53
  • Poorly differentiated thyroid carcinoma (PDTC)
  • Thyroid carcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Lavra, L., Ulivieri, A., Rinaldo, C., Dominici, R., Volante, M., Luciani, E., ... Sciacchitano, S. (2009). Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. Journal of Pathology, 218(1), 66-75. https://doi.org/10.1002/path.2510

Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. / Lavra, Luca; Ulivieri, Alessandra; Rinaldo, Cinzia; Dominici, Roberto; Volante, Marco; Luciani, Emidio; Bartolazzi, Armando; Frasca, Francesco; Soddu, Silvia; Sciacchitano, Salvatore.

In: Journal of Pathology, Vol. 218, No. 1, 05.2009, p. 66-75.

Research output: Contribution to journalArticle

Lavra, L, Ulivieri, A, Rinaldo, C, Dominici, R, Volante, M, Luciani, E, Bartolazzi, A, Frasca, F, Soddu, S & Sciacchitano, S 2009, 'Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas', Journal of Pathology, vol. 218, no. 1, pp. 66-75. https://doi.org/10.1002/path.2510
Lavra, Luca ; Ulivieri, Alessandra ; Rinaldo, Cinzia ; Dominici, Roberto ; Volante, Marco ; Luciani, Emidio ; Bartolazzi, Armando ; Frasca, Francesco ; Soddu, Silvia ; Sciacchitano, Salvatore. / Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. In: Journal of Pathology. 2009 ; Vol. 218, No. 1. pp. 66-75.
@article{94560681b90048c6af78ed14f7178354,
title = "Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas",
abstract = "Galectin-3 (Gal-3) is an anti-apoptotic molecule of the j-galactoside-binding lectin family. Gal-3 is down-regulated by wt-p53 and this repression is required for p53-induced apoptosis. Since poorly differentiated thyroid carcinomas (PDTCs) and anaplastic thyroid carcinomas (ATCs) frequently harbour p53 mutations, we asked whether Gal-3 expression and activity could be influenced by such mutations in these tumours. We found a positive correlation between Gal-3 expression and p53 mutation in human thyroids and in thyroid carcinoma cell lines (TCCLs) harbouring different p53 mutations. Gal-3 was over-expressed in most ATCs and TCCLs, especially those with the most frequently detected p53 mutation (p 53R273H). Over-expression of p53 R273H in twop53-null cells (SAOS-2 and SW-1736) as well as in two wt- p53-carrying TCCLs (TPC-1 and K1), stimulated Gal-3 expression, while interference with p53R273H endogenous expression in ARO cells down-regulated Gal-3 expression. Conversely, over-expression of wt-p53 in ARO cells restored the inhibitory effect on Gal-3 expression. ARO cells are highly resistant to apoptosis and express both p53 and Gal-3, which are increased upon cisplatin treatment. Interference with Gal-3 expression in these cells stimulated their chemosensitivity. In conclusion, gain-of-function p53 mutant acquires the de novo ability to stimulate Gal-3 expression and to increase chemoresistance in ATCs.",
keywords = "Anaplastic thyroid carcinoma (ATC), Apoptosis, Chemoresistance, Clonogenic assay, Galectin-3, Human thyroid carcinoma cell lines, P53, Poorly differentiated thyroid carcinoma (PDTC), Thyroid carcinoma",
author = "Luca Lavra and Alessandra Ulivieri and Cinzia Rinaldo and Roberto Dominici and Marco Volante and Emidio Luciani and Armando Bartolazzi and Francesco Frasca and Silvia Soddu and Salvatore Sciacchitano",
year = "2009",
month = "5",
doi = "10.1002/path.2510",
language = "English",
volume = "218",
pages = "66--75",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas

AU - Lavra, Luca

AU - Ulivieri, Alessandra

AU - Rinaldo, Cinzia

AU - Dominici, Roberto

AU - Volante, Marco

AU - Luciani, Emidio

AU - Bartolazzi, Armando

AU - Frasca, Francesco

AU - Soddu, Silvia

AU - Sciacchitano, Salvatore

PY - 2009/5

Y1 - 2009/5

N2 - Galectin-3 (Gal-3) is an anti-apoptotic molecule of the j-galactoside-binding lectin family. Gal-3 is down-regulated by wt-p53 and this repression is required for p53-induced apoptosis. Since poorly differentiated thyroid carcinomas (PDTCs) and anaplastic thyroid carcinomas (ATCs) frequently harbour p53 mutations, we asked whether Gal-3 expression and activity could be influenced by such mutations in these tumours. We found a positive correlation between Gal-3 expression and p53 mutation in human thyroids and in thyroid carcinoma cell lines (TCCLs) harbouring different p53 mutations. Gal-3 was over-expressed in most ATCs and TCCLs, especially those with the most frequently detected p53 mutation (p 53R273H). Over-expression of p53 R273H in twop53-null cells (SAOS-2 and SW-1736) as well as in two wt- p53-carrying TCCLs (TPC-1 and K1), stimulated Gal-3 expression, while interference with p53R273H endogenous expression in ARO cells down-regulated Gal-3 expression. Conversely, over-expression of wt-p53 in ARO cells restored the inhibitory effect on Gal-3 expression. ARO cells are highly resistant to apoptosis and express both p53 and Gal-3, which are increased upon cisplatin treatment. Interference with Gal-3 expression in these cells stimulated their chemosensitivity. In conclusion, gain-of-function p53 mutant acquires the de novo ability to stimulate Gal-3 expression and to increase chemoresistance in ATCs.

AB - Galectin-3 (Gal-3) is an anti-apoptotic molecule of the j-galactoside-binding lectin family. Gal-3 is down-regulated by wt-p53 and this repression is required for p53-induced apoptosis. Since poorly differentiated thyroid carcinomas (PDTCs) and anaplastic thyroid carcinomas (ATCs) frequently harbour p53 mutations, we asked whether Gal-3 expression and activity could be influenced by such mutations in these tumours. We found a positive correlation between Gal-3 expression and p53 mutation in human thyroids and in thyroid carcinoma cell lines (TCCLs) harbouring different p53 mutations. Gal-3 was over-expressed in most ATCs and TCCLs, especially those with the most frequently detected p53 mutation (p 53R273H). Over-expression of p53 R273H in twop53-null cells (SAOS-2 and SW-1736) as well as in two wt- p53-carrying TCCLs (TPC-1 and K1), stimulated Gal-3 expression, while interference with p53R273H endogenous expression in ARO cells down-regulated Gal-3 expression. Conversely, over-expression of wt-p53 in ARO cells restored the inhibitory effect on Gal-3 expression. ARO cells are highly resistant to apoptosis and express both p53 and Gal-3, which are increased upon cisplatin treatment. Interference with Gal-3 expression in these cells stimulated their chemosensitivity. In conclusion, gain-of-function p53 mutant acquires the de novo ability to stimulate Gal-3 expression and to increase chemoresistance in ATCs.

KW - Anaplastic thyroid carcinoma (ATC)

KW - Apoptosis

KW - Chemoresistance

KW - Clonogenic assay

KW - Galectin-3

KW - Human thyroid carcinoma cell lines

KW - P53

KW - Poorly differentiated thyroid carcinoma (PDTC)

KW - Thyroid carcinoma

UR - http://www.scopus.com/inward/record.url?scp=66749085092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66749085092&partnerID=8YFLogxK

U2 - 10.1002/path.2510

DO - 10.1002/path.2510

M3 - Article

C2 - 19199318

AN - SCOPUS:66749085092

VL - 218

SP - 66

EP - 75

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 1

ER -